Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bausch & Lomb
Data analysis presented from trial of Retisert implant
November 6th, 2004
Analysis of 34-week results of an international, randomized, dose-masked, multicenter clinical trial designed to assess the safety and efficacy of the Retisert implant for the treatment of non-infectious posterior uveitis were presented. The results were presented by principal investigator Robert Devenyi, ophthalmologist-in-chief and director of Retinal Services at the University Health Network and professor of ophthalmology at the University of Toronto, Canada, at the Annual Meeting of the Retina Society in Baltimore, Maryland on Saturday, October 2, 2004. This trial was designed to confirm the results of the first pivotal trial of the implant,...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
